Compound
    Moderate Evidence

    TUDCA

    Tauroursodeoxycholic acid

    TL;DR

    TUDCA has genuine pharmacological support in cholestatic liver disease (largely as the taurine conjugate of UDCA, a licensed drug) but the supplement-market claims about mitochondria, eyes and longevity rest on animal work. Bile-acid derivatives are drugs in most jurisdictions, not gentle nutrients.

    Ideal For

    • People with clinician-supervised cholestatic liver concerns

    Avoid If

    • Biliary obstruction
    • Pregnancy without medical supervision

    Frequently Asked Questions

    Overview

    Tauroursodeoxycholic acid is ursodeoxycholic acid conjugated with taurine. UDCA itself is an approved treatment for primary biliary cholangitis and gallstone dissolution, and small head-to-head trials suggest TUDCA lowers liver enzymes at least as effectively with comparable tolerability. Beyond hepatology, TUDCA is a chemical chaperone that reduces endoplasmic reticulum stress, which has generated preclinical enthusiasm for ALS, retinitis pigmentosa, insulin resistance and neuroprotection. Human data in those areas are limited to small phase II work, some of it promising (an ALS trial combining TUDCA with sodium phenylbutyrate) but not yet decisive.

    How It Works

    • Shifts the bile acid pool toward less cytotoxic hydrophilic species
    • Reduces endoplasmic reticulum stress as a chemical chaperone
    • Inhibits mitochondrial apoptotic signalling in hepatocytes and neurons

    Quick Facts

    • Taurine conjugate of UDCA, a licensed liver drug
    • Strongest evidence is in cholestatic liver disease
    • Most neuro and eye claims come from animal models

    Benefits & Outcomes

    Liver Protection

    Liver and Detox
    Likely effective
    Moderate Evidence
    Effectiveness 4/5

    Real hepatology evidence exists, but this is a drug-class molecule that belongs under clinical supervision rather than casual self-dosing.

    Bile Flow Enhancement

    Digestive
    Likely effective
    Preliminary

    TUDCA has real evidence in cholestatic conditions, less so for general digestion.

    Health Concerns Addressed

    No linked health concerns yet.

    Supporting Research
    6 studies

    Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women

    Score: 6/10
    2010
    rct
    n=20

    Kars M, Yang L, Gregor MF

    Hepatic and muscle insulin sensitivity improved by approximately 30% with no change in adipose tissue

    View source

    Bile acids for liver-transplanted patients

    Score: 8/10
    2010
    systematic_review

    Bile acid therapy after liver transplantation showed no significant effect on mortality or graft loss.

    View source

    Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis

    Score: 6/10
    2016
    rct
    n=34

    Elia AE, Lalli S, Monsurro MR

    TUDCA-treated patients showed slower ALSFRS-R decline than placebo over 54 weeks

    View source

    Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis

    Score: 7/10
    2020
    rct
    n=137

    Paganoni S, Macklin EA, Hendrix S

    Sodium phenylbutyrate-taurursodiol slowed ALSFRS-R decline compared with placebo over 24 weeks

    View source

    Tauroursodeoxycholate-Bile Acid with Chaperoning Activity: Molecular and Cellular Effects and Therapeutic Perspectives

    Score: 5/10
    2019
    systematic_review

    Kusaczuk M

    TUDCA reduces endoplasmic reticulum stress and apoptosis across hepatic, neuronal and metabolic models

    View source

    The unexpected uses of urso- and tauroursodeoxycholic acid in the treatment of non-liver diseases

    Score: 5/10
    2014
    systematic_review

    Vang S, Longley K, Steer CJ +1 more

    Evidence supports cytoprotective effects in neurodegenerative and metabolic models with limited human trial data

    View source

    Safety Information

    Potential Side Effects

    Diarrhea is the most common effect. Nausea and abdominal discomfort occur at higher doses.

    Contraindications

    Complete biliary obstruction; do not self-treat diagnosed liver disease without hepatology input.

    Pregnancy & Breastfeeding

    Pregnancy: unknown

    Breastfeeding: insufficient_data

    Dosage Guidelines

    Dosage Used in Studies

    250-1000 mg

    Best Form

    Encapsulated TUDCA powder (purity-tested)

    Bioavailability

    Well absorbed in the ileum via bile acid transporters and enterohepatic recirculation.

    Forms Compared

    Standard supplement form, 250-500 mg units

    Licensed drug with far larger evidence base for liver disease

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.